Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement

NCT05926427 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT05926427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05926427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
August 10, 2023
Completion date
April 30, 2026
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cns lymphoma